Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? | Zendy

L. Legout | Zendy; Marc Valette | Zendy; Hervé Dezèque | Zendy; S. Nguyen | Zendy; X. Lemaire | Zendy; Caroline Loïez | Zendy; M. Caillaux | Zendy; E. Beltrand | Zendy; L. Dubreuil | Zendy; Yazdan Yazdanpanah | Zendy; H. Migaud | Zendy; É. Senneville | Zendy

Open Access

Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?

Author(s) -

L. Legout,

Marc Valette,

Hervé Dezèque,

S. Nguyen,

X. Lemaire,

Caroline Loïez,

M. Caillaux,

E. Beltrand,

L. Dubreuil,

Yazdan Yazdanpanah,

H. Migaud,

É. Senneville

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq281

Subject(s) - linezolid , medicine , rifampicin , tolerability , combination therapy , surgery , gastroenterology , adverse effect , tuberculosis , vancomycin , staphylococcus aureus , pathology , biology , bacteria , genetics

Linezolid therapy has shown high rates of clinical success in patients with osteomyelitis and prosthetic joint infections caused by Gram-positive cocci. Recent studies have demonstrated that linezolid/rifampicin combination therapy prevents the emergence of rifampicin-resistant mutations in vitro. However, linezolid/rifampicin combination-related haematological and neurological toxicities have not been evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research